Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 6Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 67Cyclophosphamide 65Gemcitabine 64toripalimab 61Paclitaxel 57Specimen Handling 55pembrolizumab 54sintilimab 53Surgical Procedures, Operative 52anlotinib 49Magnetic Resonance Spectroscopy 49Fluorouracil 49Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 39camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × olutasidenib × Clear all
NCT07471841 2026-06-01

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Hoosier Cancer Research Network

Phase 2 Not yet recruiting
25 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07411586 2026-05-15

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡